In high-risk, metastatic, or recurrent endometrial cancer, recently reported rates of HER2 overexpression by IHC were 17.2% at the 1+ or 2+ level and 7.9% at the 3+ level (van Dijk et al., 2025). Here, ERBB2 is linked to endometrial cancer.